Protocol Ledger

NCT06566586 · Phase II · RECRUITING

A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

Interventional Phase II clinical trial protocol NCT06566586 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-06 Enrollment: 80 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06566586
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)80 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06566586
Protocol FieldVerified Registry Value
NCT IdentifierNCT06566586
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment80 participants (ESTIMATED)
Registered Start Date2024-11-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI